CHMP2A

Across TCGA pan-cancer cohorts, CHMP2A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHMP2A data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CHMP2A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CHMP2A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where CHMP2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.390	0.799	.004	17	view →
HNSC	DFS	Quartile	All	0.222	0.820	.017	12	view →
UCEC	DFS	Median	All	1.000	0.939	.028	6	view →
CCRCC	DFS	Quartile	All	0.555	0.863	.025	5	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
GBM	DFS	Quartile	All	0.238	0.544	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHMP2A–LUAD (OS)

Open the LUAD breakdown →